TABLE 2.
Comparison of the prevalenve of deleterious germline mutations in this study compared to the Pritchard et al9 study
| Gene | This study (N = 150) | Pritchard et al9 NEJM (N = 692) |
|---|---|---|
| BRCA2 | 9/150 (6.0%) | 37/692 (5.3%) |
| ATM | 3/150 (2.0%) | 11/692 (1.6%) |
| CHEK2 | 3/150 (2.0%) | 10/534 (1.9%) |
| BRCA1 | 2/150 (1.3%) | 6/692 (0.9%) |
| PALB2 | 1/150 (0.7%) | 3/692 (0.4%) |
| NBN | 1/150 (0.7%) | 2/692 (0.3%) |
| MSH6 | 1/150 (0.7%) | 1/692 (0.1%) |
| CDH1 | 1/150 (0.7%) | Not analyzed |
| “VUS” | 30/150 (20.0%) | Not reported |